Andreas Wallnoefer is a seasoned biotech executive with an illustrious career, spanning over several decades. He has built an enviable track record of successful biotech ventures that have resulted in leading research and development teams to clinical Proof of Concept and regulatory approval. Wallnoefer's arsenal of skills includes executive leadership, R&D, board management, strategy & business development, venture capital, fundraising, due diligence, partnering and licensing, portfolio management, clinical development, and staff development.

He is an alumnus of several prestigious universities and has extensive educational qualifications that include an Executive MBA in Business Management from the IMD Business School, Clinical Research Fellowship in Clinical Pharmacology from Leiden University, Master of Technology Enterprise in Innovation Leadership and Management from IMD Business School, a PhD in Pharmacology, Summa cum Laude from Universität Basel, and Pharmaceutical Medicine from Universität Basel.

His professional journey has been equally impressive, and he has held various leadership positions in several organizations. Wallnoefer is currently the General Partner at BioMedPartners Ltd., where he offers his expertise in biotech ventures. He has also been the founder of "Andreas Wallnöfer Life Sciences Consulting Ltd." in the past. Wallnoefer worked at Roche for several years, where he held several key positions, including Global Head of the Cardiovascular & Metabolism R&D Disease Area Unit, Global Head Roche Pharma pRED Development, Senior Vice President, Global Head of Clinical Research & Exploratory Development (CRED), and Global Head of Early Development.

Overall, Andreas Wallnoefer is a versatile executive with extensive experience in biotech ventures and leadership roles. His expertise and knowledge will be incredibly valuable for any organization he works with.